Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21144114 | 0.95 | GPR119 (0.47) | IDH1IDH2GPR119PIK3CDSYK | |
| SCHEMBL31127073 | 0.91 | GPR119 (0.36) | IDH1IDH2GPR119PIK3CD | |
| SCHEMBL21144088 | 0.91 | GPR119 (0.36) | IDH1IDH2GPR119PIK3CD | |
| SCHEMBL19686828 | 0.85 | IDH1 (0.42) | IDH1IDH2GPR119USP30PIK3CD | |
| SCHEMBL31127135 | 0.85 | IDH1 (0.42) | IDH1IDH2GPR119USP30PIK3CD | |
| SCHEMBL21144171 | 0.82 | KCNH2 (0.40) | IDH1IDH2 | |
| SCHEMBL19686833 | 0.81 | IDH1 (0.44) | IDH1IDH2GPR119USP30PIK3CD | |
| SCHEMBL31127223 | 0.81 | IDH1 (0.44) | IDH1IDH2GPR119USP30PIK3CD | |
| SCHEMBL21143666 | 0.80 | GPR119 (0.44) | IDH1IDH2GPR119USP30PIK3CD | |
| SCHEMBL19687490 | 0.80 | IDH1 (0.41) | IDH1IDH2GPR119USP30SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885GPR119 236/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885GPR119 236/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885GPR119 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.